In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech, with a price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kostas Biliouris’s rating is based on several compelling factors that highlight Legend Biotech’s strong performance and growth potential. The company’s flagship product, Carvykti, has demonstrated impressive sales figures, surpassing analyst expectations with a 19% quarter-over-quarter growth in the second quarter of 2025. This growth is attributed to increased uptake in various treatment lines and community centers, as well as capacity expansions at key production sites.
Furthermore, Carvykti’s robust performance in both the U.S. and international markets underscores its competitive advantage and attractive benefit-risk profile compared to other therapies. The company’s diverse pipeline and ongoing approvals for earlier lines of therapy are expected to drive further growth. These factors collectively support the optimistic outlook and justify the Buy rating for Legend Biotech’s stock.
Biliouris covers the Healthcare sector, focusing on stocks such as Legend Biotech, Sarepta Therapeutics, and Centessa Pharmaceuticals. According to TipRanks, Biliouris has an average return of -8.0% and a 39.04% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $75.00 price target.